About PetIQ, Inc. 
PetIQ, Inc.
Pharmaceuticals: Major
PetIQ, Inc. is engaged in manufacturing and distributing pet medication and health and wellness products to the retail channel in the United States. The Company provides retail stores with third-party brands, including Frontline Plus, Heartgard Plus, PetAction Plus, Advecta II, Pet Lock Plus, Pet Lock Max, TruProfen and Heartshield. It distributes the products through veterinarian, retail and e-commerce channels. The Company offers its products in a range of categories, including Rx Medications, OTC Medications and Supplies, and Health and Wellness Products. Rx Medications offering includes heartworm preventatives, arthritis, thyroid, diabetes and pain treatments, antibiotics and other specialty medications. The Company manufactures Heart Shield Plus, version of Heartgard Plus, which prevents heartworm infection in dogs. The Company also manufactures TruProfen, the version of Rimadyl, which treats arthritis in dogs. OTC Medications and Supplies include flea and tick control products.
Company Coordinates 
Company Details
923 S Bridgeway Pl , EAGLE ID : 83616-6885
Registrar Details
Shareholding Snapshot
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 61 Schemes (37.03%)
Foreign Institutions
Held by 89 Foreign Institutions (13.33%)
Strategic Entities with highest holding
Highest Public shareholder
Management
Designation
Mr. McCord Christensen
Chairman of the Board, Chief Executive Officer
Mr. Mark First
Lead Independent Director
Mr. Will Santana
Director
Mr. Larry Bird
Independent Director
Mr. James Clarke
Independent Director
Mr. Scott Huff
Independent Director
Revenue and Profits:
Net Sales:
329 Million
(Quarterly Results - Jun 2024)
Net Profit:
15 Million
Pharmaceuticals: Major
USD 938 Million (Micro Cap)
27.00
NA
97.25%
1.41
13.41%
3.64






